stock share


Apple is officially jumping into the home speaker market.

It unveiled HomePod, a new 7-inch tall speaker for playing music, checking the news and controlling other connected devices in the home.

The device was previewed on stage Monday at WWDC, Apple’s annual developer conference in San Jose. The device is covered in black or white mesh and looks like the top of a microphone. Inside there are 7 tweeters, six microphones and an A8 chip — the same chip inside the iPhone.


The HomePod will go on sale later this year and costs $349.

Phil Schiller, Apple’s SVP of worldwide marketing, said on stage that the product has been in the works for “years.” But the product seems directly inspired by existing smart speakers from Amazon (AMZN, Tech30) and Google (GOOGL, Tech30). Schiller said devices like the Amazon Echo have poor sound quality, and wifi speakers like Sonos don’t have interactive voice assistants.

In an interview with Bloomberg TV, CEO Tim Cook addressed the question of whether Apple was late to the market.

stock share: Celldex Therapeutics Inc(CLDX)


Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, healthcare shares fell by 0.57 percent. Meanwhile, top losers in the sector included Amicus Therapeutics, Inc. (NASDAQ: FOLD), down 9 percent, and Celldex Therapeutics, Inc. (NASDAQ: CLDX), down 9 percent.

  • [By Todd Campbell]

    The ability to develop game-changing new drugs that revolutionize patient care could cause shares in Axovant Sciences (NYSE:AXON), Celldex Therapeutics (NASDAQ:CLDX), and Esperion Therapeutics (NASDAQ:ESPR) to soar. However, success may be tough to come by, and that makes investing in these stocks a boom or bust proposition.

  • [By WWW.KIPLINGER.COM]

    Celldex Therapeutics, Inc. (CLDX) is the first of the major biotech stocks scheduled to release an update on a pretty important drug this quarter; look for news on Oct. 8 concerning melanoma treatment glembatumumab vedotin. And thats a firm date too. Celldex is slated to present an update on the therapy at the European Society for Medical Oncology Congress.

stock share: QC Holdings Inc.(QCCO)

Advisors’ Opinion:

  • [By Monica Gerson]

    QC Holdings (NASDAQ: QCCO) shares tumbled 2.58% to reach a new 52-week low of $2.27. QC Holdings’ trailing-twelve-month profit margin is 0.60%.

    NewLead Holdings (NASDAQ: NEWL) shares dipped 6.56% to touch a new 52-week low of $0.08 after the company completed the acquisition of titles in the Viking Mine located in Kentucky, USA.

stock share: Vanguard Short-Term Government ETF(VGSH)

Advisors’ Opinion:

  • [By Donald van Deventer]

    Shorter-duration Treasury Exchange-Traded Funds: (SHY), (SHV), (IEI), (BIL), (TUZ), (FIVZ), (DTUL), (VGSH), (DTUS), (DFVS), (DFVL), (SST), (ISTB), (TBZ).

stock share: Real Goods Solar, Inc.(RGSE)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Vivint Solar Holdings along with small cap solar installation stock Sunrun Inc (NASDAQ: RUN) below their IPO prices while Real Goods Solar, Inc (NASDAQ: RGSE)has imploded after being a highflyer:

  • [By Lisa Levin]

    Shares of Real Goods Solar, Inc. (NASDAQ: RGSE) got a boost, shooting up 22 percent to $2.98 after dropping 7.89 percent on Monday. RGS Energy disclosed that it has completed its $11.5 million public offering of common stock and warrants.

  • [By Ashley Moore]

    Here is a list of the top 10 best small-cap stocks based on price gains per share so far in 2017:

    Company (Ticker)Price per Share% Change AquaBounty Technologies Inc. (Nasdaq: AQB)$14.338,646.99%Rennova Health Inc. (Nasdaq: RNVA)$3.133,333.73%China Gengsheng Minerals Inc. (OTCMKTS: CHGS)$0.021,718.18%Sunshine Heart Inc. (Nasdaq: SSH)$3.851,071.43%CTI BioPharma Corp. (Nasdaq: CTIC)$4.30991.76%Catalyst Biosciences Inc. (Nasdaq: CBIO)$6.22853.85%TearLab Corp. (Nasdaq: TEAR)$4.20707.85%Pulmatrix Inc. (Nasdaq: PULM)$3.86566.10%Real Goods Solar Inc. (Nasdaq: RGSE)$1.43498.75%Calithera Biosciences Inc. (Nasdaq: CALA)$11.70281.54%

Leave a Reply

Your email address will not be published. Required fields are marked *